Developing Depression After a Heart Attack Increases One’s Risk of Death or Readmission
When Depression Occurs is Vital to Cardiovascular Outcomes
Philadelphia, PA, October 22, 2008 – Science has found many links between depression and other serious medical illnesses, such as cancer, stroke, diabetes, and heart disease. For example, people who develop depression following a heart attack (myocardial infarction) or chest pain (angina) have an elevated risk of cardiac death or hospital readmission over the following year. In a new study scheduled for publication in the October 15th issue of Biological Psychiatry, researchers report that only episodes of depression that commenced after the coronary event were associated with increased cardiac-related morbidity and mortality, but that this increased risk was substantial.
The authors recruited patients hospitalized for ACS, and evaluated them for both lifetime and current depression. Patients were then followed for one year, with additional assessments of depression and cardiac health. Specifically, they discovered that cardiovascular outcome was not associated with prior or existing depression at the time of hospitalization. In contrast, even after controlling for traditional cardiac risk factors such as age, gender, and smoking status, depression that developed in the month after the ACS event increased the odds of cardiac readmission or death by 7 times.
John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments, “Depression may be a ‘canary in the coal mine,’ a relatively early sign of an inflammatory disease process that contributes to coronary artery disease and other medical illnesses.” He adds, “The current study suggests that depression may be heterogeneous with respect to its association with inflammatory disease processes, so it will be very important to develop biomarkers, i.e., objective and quantitative tests that can identify the subtype of depression that is a component of systemic disease processes.” Senior authors Gordon Parker and Catherine Owen further discuss: “If confirmed, [this finding] has the potential to greatly enhance the ability of health professionals to identify and allocate resources to those patients who are at the greatest risk. This finding also has the potential to shed light on the mechanisms by which post-ACS depression is associated with reduced survival; an area that is still very poorly understood.”
# # #
Notes to Editors:
The article is “Timing Is Everything: The Onset of Depression and Acute Coronary Syndrome Outcome” by Gordon B. Parker, Therese M. Hilton, Warren F. Walsh, Catherine A. Owen, Gabriella A. Heruc, Amanda Olley, Heather Brotchie, and Dusan Hadzi-Pavlovic. Dr. Walsh is affiliated with the Department of Cardiac Services, Prince of Wales Hospital, Randwick, Australia. All other authors are affiliated with the Black Dog Institute, Prince of Wales Hospital, Randwick, and the School of Psychiatry, University of New South Wales, Australia. The article appears in Biological Psychiatry, Volume 64, Issue 8 (October 15, 2008), published by Elsevier.
The authors’ disclosures of financial and conflicts of interests are available in the article. Dr. Krystal's disclosures of financial and conflicts of interests are available here.
Full text of the article mentioned above is available upon request. Contact Jayne M. Dawkins at (215) 239-3674 or email@example.com to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry is ranked 4th out of the 95 Psychiatry titles and 16th out of 199 Neurosciences titles on the 2006 ISI Journal Citations Reports® published by Thomson Scientific.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+1 215 239 3674